**RadiantCompass™**

**Transforming Rare Disease Journeys from Confusion to Clarity**

*Friends & Family Funding Presentation*

**Our Story: From Personal Crisis to Global Solution**

**The Problem That Changed Everything**

**400,000 U.S. patients receive a rare cancer diagnosis each year.** Each one faces the same devastating reality Andrew Fegley encountered when diagnosed with epithelioid mesothelioma:

*"From the first time a patient has an inclination there is 'something wrong,' they are forced into an information deficit loop. Without GPT, I'd be lost; without RadiantCompass, millions still will be."*

— Andrew Fegley, Patient Co-Founder

**Five Critical Gaps Every Rare Disease Patient Faces**

1. **"Where do I even go?"** - Patients cold-call multiple "centers of excellence," juggling separate portals at Penn, MSK, MD Anderson, and more
2. **Insurance roadblocks** - 70% of rare disease families report financial toxicity within 12 months
3. **Medical jargon chaos** - Pathology reports arrive in "12th-grade medicalese" that 9 out of 10 patients can't understand
4. **Fragmented emotional support** - Prayer, meditation, and mental health exist in separate apps, disconnected from medical care
5. **Lost data, lost hope** - Valuable patient experiences sit in siloed portals, unable to help accelerate cures for others

**Our Vision**

Transform every rare disease diagnosis—from the first incomprehensible lab result to lasting remission—into a guided path of **clarity, compassion, and choice.**

**Business Case: A $12B Market Crying for Innovation**

**Market Opportunity**

* **Global Rare Disease Population:** 400M+ people worldwide
* **U.S. Rare Cancer Patients:** 400K new diagnoses annually, 10M+ globally
* **Market Size:** $12B global rare disease real-world evidence market
* **Growth Rate:** 18% CAGR (IQVIA, 2025)

**Why Now?**

* **AI Translation Breakthrough:** We've proven AI can convert complex pathology reports into 6th-grade prose in 27 seconds
* **Regulatory Support:** FDA increasingly values real-world evidence for rare disease drug approvals
* **Patient Empowerment:** Patients demand ownership of their health data and meaningful participation in research
* **Fragmented Competition:** No single platform offers comprehensive rare disease navigation—massive whitespace opportunity

**Competitive Landscape Gap**

Current solutions focus on narrow problems:

* **Outcomes4Me** → Common cancer guidelines only
* **Belong.Life** → Peer forums without decision tools
* **AllStripes/Ciitizen** → Data aggregation without navigation

**RadiantCompass fills the whitespace** with end-to-end rare disease journey orchestration.

**RadiantCompass: The World's First Whole-Person Rare Disease Navigator**

**Our Solution**

An AI-powered platform that transforms the rare disease experience through three breakthrough capabilities:

**1. Clarity Engine - Medical Translation AI**

* Converts complex pathology, genomics, and treatment plans into plain language
* Generates personalized "ask-your-doctor" checklists
* Provides real-time explanations of medical terminology and next steps

**2. Compare-My-Care™ - Treatment Center Intelligence**

* Ranks hospitals by procedure volume, outcomes, insurance coverage, travel burden, and culture
* Eliminates the "cold-calling centers of excellence" nightmare
* Provides objective data to guide life-changing treatment decisions

**3. Care-Circle Workspace - Journey Orchestration**

* Role-based dashboards for patients, caregivers, and support circles
* Automated appointment coordination, symptom tracking, and insurance navigation
* Integrated Faith & Mind Studio for spiritual and emotional support

**Core Value Propositions**

**For Launch – Primary focus on patients, their families and Caregiver Networks**

* Navigate complex healthcare decisions with confidence
* Access plain-language medical insights instantly
* Connect with best-fit treatment centers and specialists
* Coordinate care logistics seamlessly with family support

**Secondary and Tertiary beneficiaries of the platform:**

**Healthcare Systems that can benefit from:**

* Reduction in administrative burden through automated coordination
* Improvement in patient engagement, satisfaction and outcomes
* Access to structured real-world evidence for quality improvement within their firms

**Big Pharma, Biotech and other Research Institutions that can benefit from Radiant’s Data by:**

* Helping to accelerate drug development with regulatory-grade real-world data
* Create better connections with engaged patient populations for clinical trials
* Generate evidence that helps support rare disease treatment optimization

**Technology Differentiators**

* **Proprietary Rare Disease Knowledge Graph** – we anticipate creating and connecting 7,000+ conditions through our proprietary Radiant Compass database
* **Regulatory-Grade FHIR Pipeline** ensuring research-quality data
* **Patient-Consented Real World Evidence (RWE) Data Marketplace** with revenue sharing opportunities for data contributors (future phase post-launch)

**One Possible Go-to-Market Strategy**

**Phase 1: Rare Cancer Beachhead (Months 1-18)**

**Target:** Mesothelioma, sarcoma, and rare GI cancers and/or explore other cancer focus areas

* Partner with 3-5 rare cancer patient foundations for trust and distribution
* Launch Compare-My-Care™ as a pilot and/or freemium entry point
* Build initial user base of 1,000 patients / care givers (TBD on if there is a fee and/or distributed through partnering Health networks (such as University of Penn, MSK, etc.)

**Phase 2: Healthcare System Integration (Months 12-24)**

**Target:** Cancer centers and specialty oncology practices

* White-label Clarity Engine for patient portals
* Care coordination platform for multidisciplinary teams
* Consider enabling - $2-6 Per Member / Per Month (PMPM) licensing model for health systems

**Phase 3: Payer & Employer Expansion (Months 18-36)**

**Target:** Health plans and employer benefits

* Decision support APIs for member portals
* Cost containment through optimized care pathways
* $1 PMPM API access model

**Phase 4: Research Marketplace (Months 24-48)**

**Target:** Pharmaceutical, Biotech companies and research institutions

* De-identified longitudinal data for drug development
* Patient recruitment for clinical trials
* Tiered dataset pricing with 10% patient revenue share (percentages need to be validated and market tested)

**Our Plan: 18-Month Roadmap to Success**

**Immediate Priorities (Months 1-9)**

**Build the MVP**

* Develop the branding, design and development of the following feature sets and benchmarks:
  + Establish and Finalize Branding (e.g., visual look and feel and all application aesthetics)
  + Compare-My-Care™ development with hospital ranking algorithm
  + Launch Clarity Engine with medical translation AI
  + Establish patient foundation partnerships or other partnerships that will help us to recruit and onboard beta users
  + Recruit 200 beta users through patient foundation partnerships and other channels
* **Capital Required:** ~ $750K

**Growth Phase (Months 10-18)**

**Validate Business Model**

* Secure first hospital SaaS pilot contract
* Launch payer API pilot program
* Reach 1,000 paying patients (TBD on whether patient of care institution or otherwise pays)
* Prepare 510(k) decision-support submission
* **Capital Required:** $1.3M

**Series A Preparation (Months 16-24)**

**Scale for Investment**

* Demonstrate product-market fit with enterprise contracts
* Expand to 3 additional rare cancer types
* Build regulatory moat with FDA clearance
* **Series A Target:** $8-12M at $40-60M valuation

**Long-term Vision (Years 2-5)**

**Market Leadership**

* Expand to all 7,000+ rare diseases
* International market entry
* Strategic partnerships with major health systems
* IPO readiness with dominant market position and/or significant acquisition by Tier 1 strategic buyer (e.g., Pharma, Health Insurer, Hospital System or otherwise)

**Our Ask: $2M Friends & Family Round**

**Funding Structure**

**Investment Vehicle:** SAFE (Simple Agreement for Future Equity)

* **Valuation Cap:** $15M
* **Discount:** 20% for early investors
* **Conversion:** Automatically converts to equity in Series A

**Use of Funds**

**Team Building (40% - $800K)**

* CTO and lead AI engineer
* Clinical advisory board
* Patient experience designer
* Regulatory affairs consultant

**Product and Data Development (35% - $700K)**

* MVP completion and testing
* FHIR pipeline development
* Mobile app development
* Security and compliance infrastructure

**Market Validation (15% - $300K)**

* Beta user acquisition
* Partnership development
* Pilot program execution
* Regulatory submission preparation

**Operations & Legal (10% - $200K)**

* Legal and regulatory compliance
* Office setup and equipment
* Insurance and business development
* Accounting and administrative systems

**Why Invest Now?**

**Compelling Opportunity:**

* Massive underserved market with proven pain points
* Experienced founding team with lived patient experience
* Breakthrough AI technology already validated
* Clear path to Series A with enterprise traction

**Investment Upside:**

* Ground-floor entry at attractive valuation
* High-growth market with defensible moats
* Mission-driven business with social impact
* Strong potential for strategic acquisition or IPO

**Risk Mitigation:**

* Proven founder-market fit with Andrew's patient journey
* LOIs already secured with Penn Integrative Oncology and payer innovation lab
* Regulatory pathway established with IRB draft approval
* Experienced team with $1B+ in prior project delivery

**Team: The Right People for This Mission**

**Andrew Fegley - Patient Co-Founder & CEO**

* 25+ years digital digital technology consulting and management experience
* Currently navigating epithelioid mesothelioma journey
* Authentic patient voice with deep understanding of care gaps
* Proven ability to translate complex medical information using AI

**Rob Koch & Jonathan Lupo - Co-Founders (NXT Humans)**

* Serial digital entrepreneurs with proven track record
* Deep expertise in AI/ML platform development
* $500M+ in cumulative project delivery
* Network of healthcare and technology advisors

**Connor Fegley - Co-Founder**

* Digital transformation and AI consultant
* Next-generation perspective on healthcare technology
* Family commitment to mission and patient advocacy

**Advisory Network (In Development)**

* Medical oncology expertise from leading cancer centers
* Regulatory affairs specialists with FDA experience
* Patient advocacy leaders from rare disease community
* Healthcare technology investors and operators

**Why RadiantCompass Will Win**

**Unique Advantages**

1. **Founder-Market Fit:** Andrew's lived experience provides authentic patient perspective
2. **Technology Moat:** Proprietary knowledge graph and regulatory-grade data pipeline
3. **Market Timing:** AI breakthrough enables previously impossible medical translation
4. **Partnership Strategy:** Early trust-building with patient foundations and health systems
5. **Revenue Diversification:** Multiple streams from patients, providers, payers, and research

**Success Metrics (18-Month Targets)**

* **1,000 paying patients** at $18/month average
* **2 enterprise pilot contracts** at $100K+ ARR each
* **5 patient foundation partnerships** for distribution
* **FDA 510(k) submission** for clinical decision support
* **$2M ARR** demonstrating product-market fit

**Long-term Vision**

Transform RadiantCompass into the **"GPS for rare disease navigation".**  The platform every newly diagnosed patient turns to first, every healthcare system integrates, and every researcher relies on for real-world evidence.

**Join Us: Investment in Hope**

Every rare disease patient deserves clarity, not confusion. Every family deserves support, not isolation. Every breakthrough deserves acceleration, not delay.

**RadiantCompass transforms devastating diagnoses into guided journeys of hope.**

Your investment doesn't just generate returns—it saves lives, accelerates cures, and brings light to millions facing their darkest moments.

**Let's build the future of rare disease care together.**

*"The RadiantCompass mission is to transform every rare-disease diagnosis, from the first incomprehensible lab result to lasting remission, into a guided path of clarity, compassion, and choice."*

**Next Steps**

1. **Schedule follow-up meeting** to discuss investment details
2. **Review SAFE agreement** terms and documentation
3. **Connect with patient advisors** for additional validation
4. **Join our mission** to revolutionize rare disease care

**Contact Information:**

* Andrew Fegley, CEO: [email]
* Investment Deck & Due Diligence: [portal]
* Patient Journey Demo: [available upon request]